Publicaciones en las que colabora con Javier Sastre Valera (21)

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2019

  1. Management and supportive treatment of frail patients with metastatic pancreatic cancer

    Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404

  2. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

2018

  1. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

2015

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589

  2. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

  3. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

    Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

2009

  1. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study

    Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144

  2. Recommendations on current approach to gastric cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 8, pp. 518-525

2007

  1. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the treatment of digestive tumors trial

    Journal of Clinical Oncology, Vol. 25, Núm. 27, pp. 4224-4230

2006

  1. UFT in combination with oxaliplatin: Clinical phase I study in patients with advanced or metastatic solid tumors

    Anti-Cancer Drugs, Vol. 17, Núm. 4, pp. 417-421

2005

  1. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study

    Journal of Clinical Oncology, Vol. 23, Núm. 15, pp. 3545-3551

  2. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 4, Núm. 6, pp. 384-389

2004

  1. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer

    Annals of Oncology, Vol. 15, Núm. 4, pp. 559-567

2003

  1. Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643

2001

  1. Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial

    Clinical colorectal cancer, Vol. 1, Núm. 1, pp. 43-46

2000

  1. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158

1999

  1. UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

    ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40